Loss of Heterozygosity and Mutations in the RAS-ERK Pathway Genes in Tumor Cells of Various Loci in Multiple Myeloma
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25179426 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Maiia Soloveva und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Medical Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia. Hauptthemen laut MEDLINE: Multiple Myeloma, Mutation, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Multiple myeloma (MM) is a disease characterized by spatiotemporal heterogeneity of tumor clones. Different genetic aberrations can be observed simultaneously in tumor cells from different loci, and as the disease progresses, new subclones may appear. The role of liquid biopsy, which is based on the analysis of tumor DNA circulating in the blood plasma, continues to be explored in MM. Here, we present an analysis of the STR profiles and mutation status of the KRAS, NRAS, and BRAF genes, evaluated in plasma free circulating tumor DNA (ctDNA), CD138+ bone marrow cells, and plasmacytomas. The prospective single-center study included 97 patients, with a median age of 55 years. Of these, 94 had newly diagnosed symptomatic MM, and three had primary plasma cell leukemia. It should be noted that if mutations were detected only in ctDNA, “non-classical” codons were more often affected. A variety of adverse laboratory and clinical factors have been associated with the detection of rare KRAS or NRAS gene mutations in bone marrow or ctDNA, suggesting that these mutations may be factors of an unfavorable prognosis for MM. Liquid biopsy studies provide undeniable fundamental information about tumor heterogeneity and clonal evolution in MM. Moreover, we focus on using liquid biopsy to identify new high-risk factors for MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Medical Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia.
ORCID-Profile: Maiia Soloveva, Maksim Solovev, Natalya Risinskaya, Yulia Chabaeva, Andrey Sudarikov
Zitieren
APA
Soloveva, M., Solovev, M., Risinskaya, N., Nikulina, E., Yakutik, I., Biderman, B., Obukhova, T., Chabaeva, Y., Kulikov, S., Sudarikov, A., & Mendeleeva, L. (2024). Loss of Heterozygosity and Mutations in the RAS-ERK Pathway Genes in Tumor Cells of Various Loci in Multiple Myeloma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25179426
Vancouver
Soloveva M, Solovev M, Risinskaya N, Nikulina E, Yakutik I, Biderman B, et al. Loss of Heterozygosity and Mutations in the RAS-ERK Pathway Genes in Tumor Cells of Various Loci in Multiple Myeloma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25179426
BibTeX
@article{Soloveva2024,
author = {Soloveva, Maiia and Solovev, Maksim and Risinskaya, Natalya and Nikulina, Elena and Yakutik, Igor and Biderman, Bella and Obukhova, Tatiana and Chabaeva, Yulia and Kulikov, Sergej and Sudarikov, Andrey and Mendeleeva, Larisa},
title = {Loss of Heterozygosity and Mutations in the RAS-ERK Pathway Genes in Tumor Cells of Various Loci in Multiple Myeloma},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25179426}
}
EUVIMED